Stem Cell Mobilization Performed with Different Doses of Cytarabine in Plasma Cell Myeloma Patients Relapsing after Previous Autologous Hematopoietic Cell Transplantation-A Multicenter Report by the Polish Myeloma Study Group

• Published in: Cancers Vol. 16; no. 14; p. 2588
• Main Authors: Drozd-Sokołowska, Joanna, Waszczuk-Gajda, Anna, Topczewska, Magdalena, Maciejewska, Martyna, Dutka, Magdalena, Zaucha, Jan Maciej, Szmigielska-Kapłon, Anna, Nowicki, Mateusz, Olszewska-Szopa, Magdalena, Szeremet, Agnieszka, Czyż, Anna, Kozioł, Magdalena, Hus, Marek, Mańko, Joanna, Hus, Iwona, Romejko-Jarosińska, Joanna, Kopińska, Anna, Helbig, Grzegorz, Mądry, Krzysztof, Boguradzki, Piotr, Król, Małgorzata, Snarski, Emilian, Hayden, Patrick J, Jamroziak, Krzysztof, Dwilewicz-Trojaczek, Jadwiga, Basak, Grzegorz Władysław
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 19.07.2024
• Subjects: Apheresis; Autografts; Blood platelets; CD34 antigen; Cyclophosphamide; Cytarabine; Disease prevention; Diseases; Etoposide; Failure; Hematopoietic stem cells; Multiple myeloma; Myeloma; Neutropenia; Patients; Relapse; Septic shock; Stem cell transplantation; Stem cells; Tazobactam; Toxicity; Transplantation; Poland; United States > US; plasma cell myeloma; stem cell mobilization; relapse; autologous hematopoietic cell transplantation; salvage treatment
• ISSN: 2072-6694; 2072-6694
• DOI: 10.3390/cancers16142588

Salvage autologous hematopoietic cell transplantation (auto-HCT) may be used to treat relapse of plasma cell myeloma occurring after previous auto-HCT. When an insufficient number of hematopoietic stem cells have been stored from the initial harvest, remobilization is necessary. Here, we aimed to analyze the efficacy and safety of different doses of cytarabine (total 800 vs. 1600 vs. 2400 mg/m ) for remobilization. Sixty-five patients, 55% male, with a median age at remobilization 63 years, were included. Remobilization was performed with cytarabine_800 in 7, cytarabine_1600 in 36, and cytarabine_2400 in 22 patients. Plerixafor rescue was used in 25% of patients receiving cytarabine_1600 and 27% of those receiving cytarabine_2400. Patients administered cytarabine_800 were not rescued with plerixafor. Remobilization was successful in 80% of patients (57% cytarabine_800; 86% cytarabine_1600; 77% cytarabine_2400; = 0.199). The yield of collected CD34+ cells did not differ between the different cytarabine doses ( = 0.495). Patients receiving cytarabine_2400 were at the highest risk of developing severe cytopenias, requiring blood product support, or having blood-stream infections. One patient died of septic shock after cytarabine_2400. In summary, remobilization with cytarabine is feasible in most patients. All doses of cytarabine allow for successful remobilization. Cytarabine_2400 is associated with higher toxicity; therefore, lower doses (800 or 1600 mg/m ) seem to be preferable.